Glycolic Acid

Glycolic Acid

SCHEMBL219019

O=C([O-])CO.O=C([O-])CO.O=C([O-])CO.O=C([O-])CO.O=C([O-])CO.O=C([O-])CO.[Mo+6]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.50
OR51E2 Q9H255 1/20 0.44
CASP1 P29466 1/20 0.44
FFAR3 O14843 2/20 0.39
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
MEN1 O00255 1/20 0.38
LDHA P00338 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
CA1 P00915 3/20 0.36
FAHD1 Q6P587 1/20 0.36
CA2 P00918 1/20 0.35
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycolic Acid SCHEMBL4555780 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL134226 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL14661525 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL4522823 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL21297631 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL26512 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL991430 0.91
Glycolic Acid SCHEMBL1002389 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL15441504 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL331529 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor WANHUA CHEMICAL GROUP CO., LTD. (CN) 2026-02-24 US claimed
EP-4144780-B1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO LTD (CN) 2025-12-24 EP claimed
CN-115466201-B Sulfonic acid modified polyisocyanate and preparation method thereof 万华化学集团股份有限公司 2024-05-03 CN claimed
US-20230257344-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO., LTD. (CN) 2023-08-17 US claimed
EP-4144780-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR Wanhua Chemical Group Co., Ltd. (CN) 2023-03-08 EP claimed
WO-2022257585-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR 万华化学集团股份有限公司 2022-12-15 WO claimed
CN-115466201-A Sulfonic acid modified polyisocyanate and preparation method thereof 万华化学集团股份有限公司 2022-12-13 CN claimed
CN-112175011-B Continuous preparation method of homogeneous organic molybdenum compound 中国石油化工股份有限公司 2022-09-27 CN claimed
CN-112703055-A Selective oxidation catalyst and oxidation of C in the presence of a selective oxidation catalyst2Process for the production of hydrocarbons 沙特基础工业全球技术公司 2021-04-23 CN claimed
CN-112175011-A Continuous preparation method of homogeneous organic molybdenum compound 中国石油化工股份有限公司 2021-01-05 CN claimed
US-9896776-B2 Chemical and electrochemical synthesis and deposition of chalcogenides from room temperature ionic liquids BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-02-20 US claimed
US-20160153108-A1 CHEMICAL AND ELECTROCHEMICAL SYNTHESIS AND DEPOSITION OF CHALCOGENIDES FROM ROOM TEMPERATURE IONIC LIQUIDS UNIV TEXAS (US) 2016-06-02 US claimed
US-20150329751-A1 REACTIVE COMPOSITION COMPRISING POLYAMINES AND A DISPERSION CONTAINING URETDIONE GROUPS EVONIK INDUSTRIES AG (DE) 2015-11-19 US claimed
US-20130112110-A1 CHEMICAL AND ELECTROCHEMICAL SYNTHESIS AND DEPOSITION OF CHALCOGENIDES FROM ROOM TEMPERATURE IONIC LIQUIDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2013-05-09 US claimed
US-20120129963-A1 SYNTHESIS OF NOVEL MULTIFUNCTIONAL CARDANOL'S DERIVATIVES AND THEIR USE AS HALOGEN FREE POLYURETHANIC FOAMS PRECURSORS CIMTEC LAB S.P.A. (IT) 2012-05-24 US claimed
EP-2451762-A1 SYNTHESIS OF NOVEL MULTIFUNCTIONAL CARDANOL'S DERIVATIVES AND THEIR USE AS HALOGEN FREE POLYURETHANIC FOAMS PRECURSORS Cimteclab S.R.L. (IT) 2012-05-16 EP claimed
US-5856420-A MISCIBILITY ARCO CHEMICAL TECHNOLOGY, L.P. (US) 1999-01-05 US claimed
WO-1997039063-A1 BIS(ISOBUTYRALDIMINE) OF 1,4-DIAMINOBUTANE IN HDI TRIMER AND BIURET-BASED COATINGS ARCO CHEMICAL TECHNOLOGY, L.P. (US) 1997-10-23 WO claimed
US-12637535-B2 Non-ionic hydrophilized polyisocyanates having a very low monomer content COVESTRO DEUTSCHLAND AG (DE) 2026-05-26 US disclosed
US-3954900-A POLYESTERURETHANES CASSELLA FARBWERKE MAINKUR ATIENGESELLSCHAFT (DT) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257344-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR TST, SULT1A1, SULT2A1 CA4 614/4885OR51E2 69/4885CASP1 3936/4885
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor TMT1A, SRMS, FTO CA4 1304/4885OR51E2 521/4885CASP1 1448/4885
US-20120129963-A1 SYNTHESIS OF NOVEL MULTIFUNCTIONAL CARDANOL'S DERIVATIVES AND THEIR USE AS HALOGEN FREE POLYURETHANIC FOAMS PRECURSORS EBP, CYP51A1, HSD17B7 CA4 3172/4885OR51E2 1062/4885CASP1 443/4885
US-12637535-B2 Non-ionic hydrophilized polyisocyanates having a very low monomer content NUDT1, UTS2R, PUF60 CA4 1167/4885OR51E2 1364/4885CASP1 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.